ABSTRACT. Objective. Concerns have been raised about nonadherence behavior among patients with chronic inflammatory rheumatic diseases (CIRD) receiving biologics. This nonadherence may be caused by various factors. The main objective was to explain why patients discontinue their biologics of their own accord. Methods. A quantitative and descriptive study was performed using a self-report questionnaire that was sent through the Internet to members of different patient associations. Sociodemographic data, medical and therapeutic history, management of biologic administration, previous experiences, and patients' beliefs and perceptions about treatment efficacy and side effects were studied to explain self-discontinuation (SD).
continuity, which refers to "persistence" 12 . Adherence is an emerging aspect in the field of rheumatology, particularly among patients with CIRD treated with biologics 13 . In a review by Koncz, et al, compliance rates ranged between 63% and 90% and persistence decreased steeply over time 14 . Another review from Blum, et al gave an overall range of persistence of 32.0% to 90.9% after 12 months of treatment 15 .
Poor adherence may undermine the potential therapeutic benefits of biologics by contributing to treatment failure, progression of disease, and potential comorbidities 16, 17 . Moreover, the economic burden of nonadherence is high given the high cost of biologics and the lack of benefits from partial treatment 18 . Therefore, identifying the reasons for this lack of adherence is a priority. Several authors have studied the association between adherence to biologics (estimated from pharmacy records) and some factors related to patients with CIRD, the disease, or the treatment 19, 20, 21, 22 , but to our knowledge none have used patient self-report to assess reasons for SD.
Between December 2011 and February 2012, we performed a preliminary qualitative analysis of medication adherence of patients receiving biologic therapy 23 and revealed 5 main categories to explain this behavior. The main objective of our present study was to confirm the previous figures and identify predictive factors of SD among patients with CIRD. We expected that chronology of the disease and treatments, healthcare organization, previous experiences, beliefs, relationship between the patient and the healthcare provider, perception of social support, and self-efficacy were related to SD.
MATERIALS AND METHODS
Design and study population. Ours was a prospective descriptive study. A self-report questionnaire was developed in March 2012 based on the initial qualitative phase 23 . The questionnaire consisted of closed-ended and multiple choice questions grouped into 5 categories: (1) disease-induced impairment, (2) drug regimen complexity, (3) demographic and socioeconomic characteristics of the patient, (4) relation between the patient and the healthcare system, and (5) the patient's own resources (knowledge, beliefs, experience, motivation). The questionnaire was tested in May and June 2012 on 10 patients from the Rheumatology Clinic of the Grenoble University Hospital. After validation, the questionnaire was posted on the Internet and the link was sent by e-mail to the members of 3 major French patient associations: Association Nationale de Défense contre l'Arthrite Rhumatoïde (3500 members), Association Française de Lutte Anti-Rhumatismale (3000 members), and Association France Spondylarthritites (750 members). Data were collected between June 16, 2012, and July 4, 2012. Inclusion criteria were age > 18 years and CIRD treated (or formerly treated) with at least 1 biologic DMARD. All concomitant treatments were allowed.
We left the questionnaire posted online until we reached around 10% of respondents from the initial potential pool of targeted patients.
Measurements. Various methods, direct or indirect, are approved to measure medication adherence 24 . In our quantitative analysis, we decided to look at the "SD" of biologics, which was better adapted to our self-declaration model than "nonadherence."
Assessment of discontinuation and SD. We defined discontinuation as stopping injections of a biologic either definitively, with possibly a switch to another biologic, or temporarily. Discontinuation was assessed in 2 distinct parts of the questionnaire. First, patients were asked to name their first biologic and whether this therapy was still in progress. If not, they were asked to explain the reason for the discontinuation and who had decided on it ("the physician," "in agreement with the physician," "alone and then validated by the physician," or "alone without validation by the physician"). These questions had to be answered for each biologic used. Second, patients were asked if they had already tried to space out the injections of their biologic(s). If so, they were asked the name of the specific biologic and to explain the reason behind the interruption, who made the decision, and the duration of the break (questionnaire available from the authors on request).
SD was defined as the patient's decision to stop biologic injections. Patients were considered "SD patients" if they declared having discontinued their biologic injections by themselves ("alone" or "alone and then validated by a physician"), with the exception of patients who declared having spaced out their injections because of a sign of infection or planned surgery (situations where the action was considered appropriate).
Exploration of reasons for SD.
A total of 21 different factors grouped into 3 domains were tested with SD patients in the univariate analysis:
(1) Sociodemographic data (6 factors): age, sex, marital status, work status, highest level of study, and place of residence.
(2) Pain, type of CIRD, disease duration, time to diagnosis, time since first biologic, number of biologic lines, number of physicians consulted since first symptoms.
Medical and therapeutic history (7 factors): pain over the last 8 days assessed by a visual analog scale (VAS) from 0 (no pain) to 10 (maximum pain), type of CIRD (RA, AS, PsA, or other), disease duration, time to diagnosis, time since first biologic, number of biologic lines, and number of physicians consulted since first symptoms. We defined a "biologic line" as each biologic drug treatment 1 patient had during their medication history (1 patient could accumulate several biologic lines). Regarding data on patients' beliefs and perceptions about treatment efficacy and side effects, an exploratory factor analysis of the questionnaire was conducted using the nonorthogonal (Direct Oblimin) method of rotation as recommended by Kline 25 and Cattell 26 . Results showed a 5-factor solution as suggested by factor scree plot explaining 59% of the variance. Then scores were calculated by adding items from each factor (or subgroup), with the hypothesis that the higher the score, the more likely patients were to self-discontinue. Univariate analyses were performed to compare characteristics between patients with RA and patients with AS, and between SD patients and other patients. The chi-square test was used for categorical data or the Fisher's exact test when appropriate, and the Student t test was used for continuous data (only for belief scores) or the Mann-Whitney U test when appropriate. The independent SD factors were tested using multivariate logistic regression, entering only variables associated with SD with a p value < 0.2 in univariate analysis. A backward stepwise selection was then performed to give the final model, which included only significant variables. The OR for SD against no SD and the associated 95% CI are reported for these variables. We considered p values < 0.05 significant. Statistical analyses were performed with STATA 12.0 (StataCorp). This research was approved by the CECIC ("comité d'éthique des centres d'investigations cliniques") Rhône-Alpes Auvergne (No. IRB: 5891).
RESULTS
Characteristics of the population. Out of the 606 patients who responded to the questionnaire during the inclusion period, 581 were retained. Twenty-five patients were excluded: 15 answered twice, 9 gave inconsistent and/or inadequate data, and 1 was under 18 years old. Table 1 . All counties in France except 8 were represented, indicating a good geographical distribution of our sample throughout the country. Medical and therapeutic history. The mean duration of the disease since first symptoms was 14.9 years for the AS group, 16.5 years for the RA group, and 18.5 for the other CIRD group. The mean time between first symptoms and diagnosis for the AS, RA, and other CIRD groups was 5.9 years, 2.5 years, and 5.9 years, respectively. Finally, the mean period between diagnosis and the first biologic line tried was 5.3 years, 8.5 years, and 6.1 years, respectively.
Average pain over the previous 8 days was estimated as 4.2/10 on the VAS, 4.5/10 for the AS group, 3.8/10 for the RA group, and 4.1 for the other CIRD group (p = 0.002). Patients reported having consulted an average of 4.7 different physicians since their first symptoms. A total of 1044 biologic lines were described (for each patient, this corresponded to a sequence of 1 or more biologic drugs), with a median of 2 biologic lines per patient (range from 1 to 7 Patients' beliefs and perceptions about the efficacy of biologics and side effects. Scores were calculated for each factor with the hypothesis that the higher the score, the more patients actually experienced SD ( Table 2) . Discontinuation. About 74% of patients discontinued their biologics (431/581) at least once, and 79% of biologic lines were discontinued (823/1044). Among these discontinuations, 56.7% involved a switch to another biologic (467/823), 13.1% were definitive (108/823), and 30.1% were restarted (248/823). Regarding patients who restarted biologics, 39.6% (203/581) declared having spaced out their biologic injections, with a mean gap of 24.1 days. Among the 431 patients who discontinued their biologics at least once, 86 patients were included in the SD group, which means that 20% of discontinuations were the patient's decision.
Among the 581 patients of our study, 14.8% experimented with SD. Fifty-seven percent (49/86) were patients with AS, 36% (31/86) were patients with RA, and 7% (6/86) were patients with other CIRD (p = 0.638), representing about 10% of biologic lines (112/1044). Reasons for these SD are presented in Table 3 . Factors related to SD. Factors significantly related to SD by univariate analysis (for a p value < 0.05) were more than 1 line of biologics tested, self-administered biologics, use of CAM, negative beliefs about treatment, and lack of medical and social support (Table 4 and Table 5 ). Significant factors related to SD in the univariate model for a p value < 0.2 were entered into the multivariate model. Factors associated with SD in our sample of patients with CIRD (for a p value < 0.05) were lower level of pain, more than 1 line of biologics tried, self-administered biologics, negative beliefs about treatment, and lack of perceived medical and social support.
Type of CIRD or sex were not associated to adherence.
DISCUSSION
In our study, 14.8% of patients with CIRD self-discontinued their biologics. Five predictive factors of this SD were identified: pain (low level), treatment history (more than 1 line of biologics tried), self-administration of injections, negative beliefs about treatment, and lack of perceived medical and social support. Only 1 study, from Bluett, et al 17 , used a self-reported questionnaire to quantify nonadherence, defined as whether the previously due dose of biologic therapy was reported as not taken on the day agreed with the healthcare professional. To our knowledge, even if our questionnaire was validated on a small sample, our study is the only one trying to predict nonadherence with a self-questionnaire, exploring treatment management, previous experiences, and patient's beliefs and (6, (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) 6.0 (6, (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) 6.0 (6, 3-11) 0.927 Medical and social support, out of 12 patients, high score = lack of support 6.4 (6, (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) 6.9 (7, (3) (4) (5) (6) (7) (8) (9) (10) (11) 6.3 (6, (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) 0.003 Expected objective of the treatments, out of 12 patients, high score = negative expected objective 6.1 (6, (3) (4) (5) (6) (7) (8) (9) (10) (11) 6.1 (6, (3) (4) (5) (6) (7) (8) (9) 6.1 (6, 3-11) 0.810 SD: self-discontinuation; SE: self-efficacy. perceptions about treatment to determine reasons for nonadherence among patients with CIRD.
Our sample came from 3 patients' associations: 1 composed of patients with RA, 1 of patients with AS, and 1 of all types of CIRD. Compared with patients with CIRD in a US cohort, the median age of patients with AS and patients with RA was similar (42 and 55 years in our study vs 43 and 50 years in the US study, respectively), but the sex ratio was very different, with a predominance of women (0.4, 0.2, and 0.4 vs 1.5, 0.3, and 1.00, respectively) 27 . Further, we also had more patients with AS in our sample than in a French cohort (60.4% vs 41.6%, respectively) and fewer patients with RA (33.7% vs 50%) 28 . These differences may be explained by our use of the Internet, which may be more accessible for younger people, such as patients with AS, and also by the overrepresentation of women in the patient associations we targeted. The need to use the Internet may have also selected patients with better educational and social status, which was higher in our study compared with the national data (the National Institute for Statistics and Economic Studies, 2009).
Out of the 581 patients included, about 15% self-discontinued. This estimate is in the same range as that of Bluett, et al (27% of self-declared nonadherence, all causes confounded) 17 . Our results are in the lower range of rates found in the literature 14 ; it may be underestimated because the rate of SD was based on self-reports that required patients to recall details of past experiences (such as dates and names of drugs). Moreover, we should not forget the social desirability bias, whereby patients report an overly optimistic estimate of their adherence to treatment 29 .
Concerning our sample size, we consider that the maximum number of explanatory variables that can be included in a multivariate model is 1 for 10 to 15 events (to avoid the risk of overadjustment). In our study, we identified 86 events (86 patients who experimented with SD); therefore, we could include 9 variables maximum in our multivariate analysis. In practice, we included 8 variables (or factors) because these were significantly related to SD for a p value < 0.2 in our univariate analysis (on the 21 factors tested). Finally, a backward stepwise selection was then performed to give the final model, with 5 independent SD factors (for a p value < 0.05). Table 4 . Variables associated with SD in univariate analysis for a p value < 0.2 and included in the multivariate analysis.
Various Factors
All Patients, n = 581, n (%) SD Patients, n = 86, n (%) Others, n = 495, n (%) p The first factor related to SD in our study was pain. The more pain the patient experienced, the better their adherence to their biologic. This correlation was independent of the type of disease. Similar results have been reported in fibromyalgia 30 . However, pain was measured over the last 8 days, while participants may have discontinued their biologics far longer ago. Further investigation should analyze the evolution of pain during time and its link to adherence. Relief from pain could be interpreted by the patient as a remission, which may lead to discontinuation 11, 31 . In contrast, pain leading up to the next injection may be perceived as a treatment efficacy, which is the most influential factor for longterm persistence according to Brod, et al 32 .
The duration of therapy seems to be a major component of adherence. Our results show that the number of different lines of therapy tried by the patient is an independent factor for discontinuation. Persistence to biologic treatments decreases with time, as Koncz, et al reported in a review of the literature 14 .
According to the literature, the previous experience of side effects is also a major driver of discontinuation 32, 33, 34 . In our study, more than 70% of patients declared having already felt side effects. However, no significant correlation with SD was found.
There is little evidence of the link between CAM and adherence. Our univariate analysis suggests that patients who self-discontinued were more likely to use CAM than others. Westhoff and Zink showed that a preference for CAM was the strongest risk predictor of lack of adherence to DMARD therapy among patients with RA 35 . In our multivariate model, this relationship does not remain significant.
In our study, patients who self-administered their biologics were also more predisposed to discontinue their biologics compared with patients whose injection was given by someone else. A qualitative study has suggested that the most critical period concerning adherence to self-injectable treatment is the first month of therapy 32 . During this period, patients need encouragement and support to continue selfadministered treatment.
The relationship between drug adherence and beliefs about medication among patients with RA was described by Neame, et al using the Belief about Medicines Question naire 36 . In line with this, we concluded a significant correlation between negative beliefs and SD (impression that treatment hurts more than does good, and that it is like a poison).
Further, we found that medical and social support were significantly related to SD, which suggests that a supportive environment may improve adherence to a biologic. Regarding internal resources, we found no significant correlation between self-efficacy and SD in our study, although the literature reports this factor as an important determinant of adherence 37, 38 . However, de Klerk, et al 37 and Brus, et al 38 assessed self-efficacy among patients with conventional DMARD only and did not use the same questionnaire.
Our study identified several components of SD behavior among patients with CIRD receiving biologics. Pain, treatment history, self-administration of injections, beliefs about treatment, and medical and social support are all factors to take into consideration when a patients with CIRD is prescribed a biologic. These patterns may be useful to better target patients who are more likely to discontinue their biologics by themselves, and to adapt our patient education programs. In the light of these predictive factors of SD, we have identified 3 major educational objectives for patients with CIRD receiving biologics: (1) to improve knowledge about the efficacy and side effects of biologics, and to identify and help modify negative beliefs, (2) to enhance medical and social support, especially during the first month of self-administered therapy, and (3) to enhance motivation over the longterm with the implementation of a regular followup program to ensure longterm adherence.
